Statins for Treatment of Primary Intracerebral Hemorrhage

Launched by THE SECOND HOSPITAL OF ANHUI MEDICAL UNIVERSITY · Jul 20, 2025

Keywords

ClinConnect Summary

This clinical trial is studying whether a medication called atorvastatin (a type of statin usually used to lower cholesterol) is safe and helpful for people who have had a spontaneous bleeding stroke in the brain, known as an intracerebral hemorrhage (ICH). The trial aims to start treatment within the first two days after symptoms begin and will see if atorvastatin can improve outcomes for these patients.

People who might be eligible are adults between 18 and 80 years old who have had a confirmed bleeding stroke in a specific part of the brain and who are relatively alert (with a certain level of consciousness). The bleeding should be detected within 3 to 24 hours of when symptoms started, and the volume of bleeding should fall within a certain range. Participants will receive atorvastatin treatment soon after diagnosis and will be monitored to see how well the medication works and if it is safe. People with bleeding caused by other conditions (like injury or aneurysms), those needing immediate surgery, pregnant women, or those with certain medical issues are not eligible. If you or a family member fits these criteria, this study might be an option to consider under medical guidance.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with a diagnosis of spontaneous intracerebral hemorrhage (ICH) confirmed by computed tomography (CT);
• • Age 18-80 years;
• • Hematoma located in the supratentorial region;
• • Time from symptom onset or last known well to baseline CT ranging from 3 to 24 hours;
• • Atorvastatin treatment can be initiated within 48 hours of symptom onset or last known well;
• • Glasgow Coma Scale (GCS) score ≥9;
• • Baseline hematoma volume of 5-35 mL;
• • Signed informed consent obtained.
• Exclusion Criteria:
• • ICH secondary to trauma, tumor, aneurysm, arteriovenous malformation (AVM), vascular anomaly, hemorrhagic transformation of infarction, cerebral venous thrombosis, or anticoagulant-related ICH;
• • Patients who have undergone or are scheduled for immediate surgical intervention;
• • Pregnancy or lactation;
• • Use of oral anticoagulants within 1 month prior to symptom onset;
• • Pre-stroke mRS \>1;
• • Known allergy to statins, active liver disease, liver dysfunction, or rhabdomyolysis;
• • Known terminal illness with a pre-stroke life expectancy of less than three months, or patients with planned withdrawal of care.